To evaluate the effects of melatonin supplementation on the main in vitro fertilization (IVF) outcomes during ovarian stimulation in patients with Polycystic ovarian syndrome (PCOS).
- Study Type: Interventional
Polycystic ovarian syndrome (PCOS) is a common endocrine disorder that causes infertility due to anovulation in women of reproductive age. Anovulation and also decreased oocyte and embryo quality may be cause of infertility in women with PCOS. Furthermore, the reactive oxygen species (ROS) induce oxidative stress which may be responsible for poor oocyte quality. The ROS generation from mononuclear cells is elevated in women with PCOS and a significant increment of lipid peroxidation products in women with PCOS has been reported.
Melatonin is a documented powerful free radical scavenger and a broad spectrum antioxidant. It has been observed that a non-PCOS group co-treated with inositol, folic acid, and melatonin (Inofolic Plus by LO.LI.Pharma) results in a significantly greater mean number of mature oocytes, and a lower mean number of immature oocytes in patients with low oocyte quality history when compared to treatment only with inositol and folic acid (Inofolic by LO.LI.Pharma).
The aim of the study is to evaluate the possible effects of melatonin supplementation on the main IVF outcomes during ovarian stimulation of patients with PCOS.
From July 2009 to December 2011, 358 patients with PCOS (Rotterdam criteria) were enrolled in this prospective randomized controlled trial.
- Dietary Supplement: Myo-inositol + folic acid + melatonin
- Myo-inositol (2000mg)+ folic acid (200 mcg)+ melatonin(3 mg)
- Dietary Supplement: Myo-inositol + folic acid
- Myo-inositol (2000mg) + folic acid (200 mcg)
Arms, Groups and Cohorts
- Experimental: Inofolic plus
- 178 patients
- Active Comparator: Inofolic
- 180 patients
Clinical Trial Outcome Measures
- Number of mature oocytes
- embryo quality
- Pregnancy rate
- Implantation rate
- Total dose of FSH administered
- Number of days of stimulation
- Serum estradiol levels
- Endometrial thickness
- Cancellation rate
- Incidence of moderate or severe ovaric hyperstimulation syndrome (OHSS)
Participating in This Clinical Trial
- diagnosis of PCOS
- irregular menstrual cycle (> than 28-30 days)
- normal uterine cavity
- body mass index of 20 to 26 Kg/m2
- first IVF treatment
- presence of tubal, uterine, genetics and male causes of infertility
- diagnosis of cancer
- hormonal treatment in the last six months
Gender Eligibility: Female
Minimum Age: 27 Years
Maximum Age: 38 Years
Are Healthy Volunteers Accepted: No
- Lead Sponsor
- AGUNCO Obstetrics and Gynecology Centre
- Provider of Information About this Clinical Study
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.